Residency · Residency · Endocrinology

Calcium and Bone Metabolism

Calcium Homeostasis

Calcium Distribution

Total body calcium amounts to approximately 1 kilogram, with 99% residing in bone as hydroxyapatite crystals and only 1% distributed between the extracellular fluid and intracellular compartments. Serum total calcium ranges from 8.5 to 10.5 mg/dL (2.1-2.6 mmol/L) and exists in three fractions: ionized or free calcium (50%), which is the biologically active form; albumin-bound calcium (40%); and calcium complexed with anions such as phosphate and citrate (10%). Because of the significant albumin-bound fraction, total calcium must be corrected for albumin levels using the formula: corrected calcium equals measured calcium plus 0.8 multiplied by the difference between 4.0 and the measured albumin. Ionized calcium, with a normal range of 4.5-5.3 mg/dL (1.12-1.32 mmol/L), is the most accurate measurement and is not affected by albumin concentration or pH changes. The effect of acid-base status on calcium binding is clinically important: alkalosis increases calcium binding to albumin, thereby decreasing ionized calcium and potentially producing symptoms of hypocalcemia, while acidosis has the opposite effect.

Calcium Absorption

Dietary calcium absorption is relatively inefficient, with only 25-35% of ingested calcium being absorbed, predominantly in the duodenum and proximal jejunum. Absorption occurs through two distinct mechanisms. Active transcellular transport is vitamin D-dependent and involves the TRPV6 calcium channel on the apical membrane, intracellular transport via calbindin-D9k, and basolateral extrusion through PMCA1b. Passive paracellular transport occurs throughout the intestine, is concentration-dependent, and accounts for the majority of absorption at high calcium intake levels.

Factors that enhance calcium absorption include 1,25-dihydroxyvitamin D (calcitriol), acidic luminal pH, lactose, and pregnancy. Factors that reduce absorption include vitamin D deficiency, high phytate or oxalate intake, malabsorption syndromes, aging, PPI use (which has a modest effect), and celiac disease.

Renal Calcium Handling

The kidney plays a critical role in calcium homeostasis, reabsorbing 98% of filtered calcium and excreting only 2%. In the proximal tubule, 60-70% of filtered calcium is reabsorbed passively via the paracellular route, following sodium transport. The thick ascending limb of the loop of Henle reabsorbs 20-25% of calcium, also via the paracellular route through claudin-16 and claudin-19, driven by the lumen-positive transepithelial voltage generated by NKCC2 and ROMK channels. The distal convoluted tubule, although handling only 5-10% of filtered calcium, is the site of active transcellular reabsorption that is tightly regulated by PTH and calcitriol, operating through the TRPV5 channel, calbindin-D28k, NCX1, and PMCA1b.

The calcium-sensing receptor (CaSR), expressed in the thick ascending limb and distal convoluted tubule as well as on parathyroid glands, plays a central integrating role. When activated by high extracellular calcium, CaSR inhibits calcium reabsorption in the kidney, promoting calciuria, while simultaneously suppressing PTH secretion from the parathyroid glands.

Key Regulatory Hormones

Parathyroid Hormone (PTH)

PTH is an 84-amino acid peptide synthesized and secreted by the parathyroid glands, of which there are typically four, each weighing approximately 30-50 mg. Its secretion is exquisitely regulated by the CaSR on parathyroid cells: low extracellular ionized calcium stimulates PTH release, while high calcium suppresses it. The rapid half-life of intact PTH, just 2-4 minutes, enables precise moment-to-moment regulation of calcium homeostasis.

PTH exerts its calcium-raising effects through coordinated actions on three organ systems. In bone, PTH increases osteoclast-mediated bone resorption indirectly by upregulating RANKL expression on osteoblasts, releasing calcium and phosphate from the skeletal reservoir. In the kidney, PTH increases calcium reabsorption in the distal tubule, decreases phosphate reabsorption in the proximal tubule (by downregulating NaPi-2a and NaPi-2c transporters), and stimulates 1-alpha-hydroxylase activity, thereby increasing production of 1,25-dihydroxyvitamin D. In the intestine, PTH acts indirectly through the increased calcitriol levels to enhance calcium and phosphate absorption. The net effect of PTH action is to raise serum calcium, lower serum phosphate, and increase 1,25-dihydroxyvitamin D.

Vitamin D

Vitamin D exists in two principal forms: vitamin D3 (cholecalciferol), which is produced in the skin from 7-dehydrocholesterol upon UVB radiation exposure and is also obtained from dietary sources such as fatty fish, fortified foods, and supplements; and vitamin D2 (ergocalciferol), derived from plant and fungal sources through the diet or supplements.

The hepatic hydroxylation of vitamin D by CYP2R1 produces 25-hydroxyvitamin D (25(OH)D), which is the major circulating form with a half-life of 2-3 weeks and serves as the best indicator of vitamin D status. The Endocrine Society defines sufficiency as greater than 30 ng/mL (75 nmol/L), insufficiency as 20-29 ng/mL, and deficiency as less than 20 ng/mL (below 50 nmol/L), while the Institute of Medicine uses a threshold of 20 ng/mL for sufficiency.

The renal hydroxylation by CYP27B1 (1-alpha-hydroxylase) produces 1,25-dihydroxyvitamin D (calcitriol), the biologically active hormone with a half-life of only 4-6 hours. Calcitriol production is tightly regulated by PTH, calcium, phosphate, and FGF23. Its actions include increasing intestinal calcium and phosphate absorption, increasing renal calcium reabsorption, modulating bone turnover, and exerting immunomodulatory effects. The inactivation pathway operates through CYP24A1 (24-hydroxylase), producing 24,25-dihydroxyvitamin D. Mutations in CYP24A1 cause infantile hypercalcemia due to excess calcitriol accumulation.

FGF23 (Fibroblast Growth Factor 23)

FGF23, produced by osteocytes, has emerged as a key phosphate-regulating hormone that has fundamentally expanded the understanding of mineral metabolism. Its actions include increasing renal phosphate excretion by downregulating NaPi-2a and NaPi-2c transporters in the proximal tubule and inhibiting 1-alpha-hydroxylase activity, thereby decreasing calcitriol production. FGF23 requires the co-receptor alpha-Klotho for signal transduction. Its secretion is stimulated by high phosphate intake, 1,25-dihydroxyvitamin D, and PTH (indirectly).

The clinical significance of FGF23 is substantial. In chronic kidney disease, elevated FGF23 contributes to secondary hyperparathyroidism and renal osteodystrophy and is independently associated with cardiovascular mortality. Excess FGF23 is the pathogenic driver in tumor-induced osteomalacia and X-linked hypophosphatemia, while FGF23 deficiency underlies tumoral calcinosis.

Calcitonin

Calcitonin is a 32-amino acid peptide produced by the thyroid C cells. Its physiological actions include inhibiting osteoclast-mediated bone resorption (though this effect is weak in adults) and promoting renal calcium excretion. While calcitonin serves as an important tumor marker for medullary thyroid carcinoma and has therapeutic applications in the acute management of hypercalcemia and Paget disease, its physiological role in adult calcium homeostasis is minimal.

<image>A comprehensive diagram of calcium homeostasis showing the integrated actions of PTH, vitamin D, and FGF23. Central element: serum calcium level in a balance beam. Three organ systems around the periphery: (1) Intestine - show calcium and phosphate absorption regulated by 1,25(OH)2D with TRPV6 channel and calbindin. (2) Kidney - show PTH increasing calcium reabsorption in DCT (via TRPV5), decreasing phosphate reabsorption in PT (via NaPi-2a), and stimulating 1-alpha-hydroxylase to produce calcitriol; show FGF23 increasing phosphate excretion and suppressing calcitriol. (3) Bone - show PTH stimulating RANKL/OPG on osteoblasts leading to osteoclast activation and calcium/phosphate release; show osteocytes producing FGF23. Include feedback loops: low calcium → PTH release → bone resorption + renal calcium retention + calcitriol production → calcium rises → CaSR suppresses PTH. Use green arrows for stimulation and red for inhibition.</image>

Bone Biology

Bone Composition

Bone is a composite tissue consisting of an organic matrix (35%) and inorganic mineral (65%). The organic matrix is predominantly type I collagen, comprising approximately 90%, along with non-collagenous proteins including osteocalcin, osteopontin, and bone sialoprotein. The inorganic mineral component, hydroxyapatite [Ca10(PO4)6(OH)2], provides rigidity and compressive strength to the skeleton.

Bone Cells

Three principal cell types mediate bone homeostasis. Osteoblasts are bone-forming cells derived from mesenchymal stem cells that secrete type I collagen, osteocalcin, and alkaline phosphatase. Their activity is regulated by Wnt signaling, bone morphogenetic proteins (BMP), and intermittent PTH exposure. Osteocytes, representing 90-95% of all bone cells, are terminally differentiated osteoblasts that become embedded within the bone matrix. They function as mechanosensors and produce two critically important regulatory molecules: sclerostin (encoded by the SOST gene), which inhibits Wnt signaling and thereby inhibits bone formation, and FGF23. Osteocytes communicate through an extensive canalicular network known as the lacunar-canalicular system. Osteoclasts are bone-resorbing cells derived from the monocyte/macrophage lineage that are multinucleated and resorb bone by secreting acid (via H+-ATPase) and proteases (particularly cathepsin K) within a sealed resorption lacuna (Howship lacuna).

RANK/RANKL/OPG System

The RANK/RANKL/OPG system represents the final common pathway for osteoclast regulation and has become one of the most therapeutically relevant pathways in bone biology. RANKL, produced by osteoblasts and osteocytes, binds to RANK on osteoclast precursors, stimulating their differentiation and activation. OPG (osteoprotegerin) is a decoy receptor produced by osteoblasts that binds RANKL before it can engage RANK, thereby blocking osteoclast activation. The ratio of RANKL to OPG determines the net level of bone resorption: a high ratio drives increased resorption, while a low ratio favors decreased resorption.

Continuous PTH exposure increases RANKL and decreases OPG expression, promoting bone resorption -- a key distinction from the anabolic effects of intermittent PTH exposure. The therapeutic relevance of this system is exemplified by denosumab, a monoclonal antibody that mimics OPG by binding RANKL and potently inhibiting osteoclast-mediated bone resorption.

Wnt Signaling Pathway

The canonical Wnt signaling pathway is critical for osteoblast differentiation and bone formation. Wnt ligands bind to the Frizzled/LRP5/6 receptor complex, stabilizing beta-catenin, which translocates to the nucleus and activates gene transcription programs that promote osteoblast activity. Sclerostin, produced by osteocytes, inhibits Wnt signaling by binding to LRP5/6, thereby reducing bone formation. Sclerostin expression is physiologically downregulated by mechanical loading and intermittent PTH exposure. DKK1 is another endogenous Wnt inhibitor. The therapeutic application of this pathway is romosozumab, an anti-sclerostin antibody that disinhibits Wnt signaling, producing a unique dual effect of simultaneously increasing bone formation and decreasing bone resorption.

Bone Remodeling

Bone remodeling is a continuous, lifelong process in which old or damaged bone is replaced with new bone. A complete remodeling cycle takes approximately 4-6 months and proceeds through defined phases: activation, resorption (2-4 weeks), reversal, formation (4-6 months), and quiescence. This coordinated process occurs within the basic multicellular unit (BMU), in which osteoclast and osteoblast activities are tightly coupled.

Bone remodeling can be monitored through specific biochemical markers. Formation markers include P1NP (procollagen type 1 N-terminal propeptide), which is the preferred formation marker, bone-specific alkaline phosphatase, and osteocalcin. Resorption markers include CTX (C-terminal telopeptide of type 1 collagen), which is the preferred resorption marker, NTX, and TRAP-5b. CTX should be measured from a fasting morning sample due to diurnal variation and is used extensively for monitoring antiresorptive therapy.

<image>A bone remodeling cycle diagram showing the basic multicellular unit (BMU). Illustrate the sequential phases in a curved timeline: (1) Activation phase - osteocyte signaling initiates remodeling at a microdamage site. (2) Resorption phase (2-4 weeks) - multinucleated osteoclasts in Howship lacunae dissolving mineral and matrix; show acid and cathepsin K secretion. (3) Reversal phase - macrophage-like cells cleaning the resorption pit; coupling signals released. (4) Formation phase (4-6 months) - osteoblasts laying down new osteoid matrix; some becoming embedded as osteocytes. (5) Mineralization - hydroxyapatite crystals deposited in collagen matrix. Include the RANKL/OPG system: osteoblasts expressing RANKL stimulating osteoclasts via RANK, and OPG as decoy receptor. Show sclerostin from osteocytes inhibiting Wnt/bone formation. Label all cell types and key molecular signals. Use medical textbook illustration style.</image>

Bone Turnover Markers in Clinical Practice

Formation Markers

P1NP is the preferred formation marker, reflecting osteoblast collagen synthesis. It increases in response to anabolic therapy such as teriparatide and is suppressed by antiresorptive agents including bisphosphonates and denosumab. Bone-specific alkaline phosphatase (BSAP) reflects osteoblast activity and is elevated in Paget disease, osteomalacia, and bone metastases. Osteocalcin, produced by osteoblasts and vitamin K-dependent, is less well standardized across assays.

Resorption Markers

CTX is the preferred resorption marker, measured from a fasting morning sample, and responds rapidly to bisphosphonate therapy with a nadir at 3-6 months, making it useful for monitoring adherence and therapeutic adequacy. NTX, measured in urine or serum, offers similar clinical utility. TRAP-5b is osteoclast-specific and has the advantage of not being affected by renal clearance.

Clinical Utility

In clinical practice, bone turnover markers serve several important functions. Monitoring antiresorptive therapy by demonstrating CTX suppression of greater than 30-40% from baseline indicates an adequate bisphosphonate response. Monitoring anabolic therapy through P1NP increase confirms a response to teriparatide or abaloparatide. Drug holiday decisions may be informed by rising CTX levels, which suggest the need to resume therapy. However, bone turnover markers are not recommended for the diagnosis of osteoporosis or for fracture risk assessment, which should rely on DXA and FRAX.

Calcium and Vitamin D Requirements

Recommended Daily Intake

Daily calcium recommendations are 1000 mg for adults aged 19-50 and males aged 51-70, and 1200 mg for women over 50 and all adults over 70. Vitamin D recommendations are 600 IU daily for adults under 70 and 800 IU daily for adults over 70, per the IOM, while the Endocrine Society recommends 1500-2000 IU daily for adults at risk of deficiency. Dietary calcium is preferred over supplemental calcium due to better absorption and less concern regarding vascular calcification. Among calcium supplements, calcium carbonate contains 40% elemental calcium but requires stomach acid for absorption and should be taken with food, while calcium citrate contains 21% elemental calcium but is acid-independent and can be taken at any time, making it preferred in patients with achlorhydria or on PPI therapy.

Vitamin D Replacement

For vitamin D deficiency (25(OH)D below 20 ng/mL), a loading regimen of 50,000 IU ergocalciferol or cholecalciferol weekly for 6-8 weeks is recommended, followed by maintenance dosing of 1500-2000 IU daily. Cholecalciferol (D3) is preferred over ergocalciferol (D2) for maintenance because of its longer half-life and more consistent effect on 25(OH)D levels. Obese patients, those with malabsorption, and patients on medications such as anticonvulsants or glucocorticoids may need 2-3 times higher doses. Vitamin D toxicity typically requires chronic ingestion of more than 10,000 IU daily or more than 50,000 IU weekly and presents with hypercalcemia, hypercalciuria, and nephrocalcinosis, with 25(OH)D levels usually exceeding 150 ng/mL.

Key Clinical Pearls

• Always check ionized calcium (or correct total calcium for albumin) before interpreting calcium levels; hypoalbuminemia is the most common cause of apparent hypocalcemia in hospitalized patients
• PTH raises calcium and LOWERS phosphate (phosphaturic effect); concurrent hypercalcemia and hypophosphatemia points to PTH excess
• FGF23 is increasingly recognized as a key mediator of phosphate wasting and vitamin D metabolism; elevated FGF23 in CKD drives secondary hyperparathyroidism and is independently associated with cardiovascular mortality
• Sclerostin and the Wnt pathway represent a paradigm shift in understanding bone formation; romosozumab (anti-sclerostin) is the first agent that simultaneously increases formation and decreases resorption ("dual effect")
• CTX measured fasting in the morning is the preferred bone resorption marker for monitoring bisphosphonate therapy; a >30-40% reduction confirms adequate treatment response
• The RANK/RANKL/OPG system is the final common pathway for osteoclast regulation; denosumab (anti-RANKL) is the therapeutic application of this biology; its effects are fully reversible upon discontinuation (unlike bisphosphonates)

References

1. Goltzman D. "Physiology of Calcium-Phosphorus Metabolism." In: Endotext, MDText.com, 2019.
2. Eastell R, et al. "Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab. 2019;104(5):1595-1622.
3. Fukumoto S, Martin TJ. "Bone as an Endocrine Organ." Trends Endocrinol Metab. 2009;20(5):230-236.
4. Holick MF, et al. "Evaluation, Treatment, and Prevention of Vitamin D Deficiency: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab. 2011;96(7):1911-1930.
5. Baron R, Kneissel M. "WNT Signaling in Bone Homeostasis and Disease: From Human Mutations to Treatments." Nat Med. 2013;19(2):179-192.

Read this lecture as Markdown